Brii Biosciences Limited (SEHK: 2137)
Health Care · Biotechnology · CN
HK$0.86
-3.37% today · -56.3% 1Y
Brii Biosciences Limited (SEHK: 2137) operates in the Biotechnology industry within the Health Care sector. The company is valued at $79.11M and employs 80 people.
Over the last twelve months the share price has lost 56.3%, trading between 0.82 and 2.13.
Tweenvest scores Brii Biosciences Limited across four factors: quality 42/100, value 48/100. Its strongest factor is value.
2137 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $79.11M
- Revenue (TTM)
- $5.13M
- P/E
- —
- EPS
- -0.24
- Dividend yield
- —
- Beta (5Y)
- 1.25
- 52-week high
- HK$2.13
- 52-week low
- HK$0.82
- Avg volume (3M)
- —
- Shares outstanding
- 721.85M
- Employees
- 80
- Next earnings
- —
About Brii Biosciences Limited
Founded in Beijing, China, in 2017, Brii Biosciences Limited is a biopharmaceutical firm dedicated to discovering and developing innovative therapies for infectious diseases and central nervous system disorders. Its diverse pipeline features: early-stage (Phase 1) compounds BRII-778 and BRII-732 for treating HIV; a multifaceted approach to Hepatitis B (HBV) including a Phase 2 combination study of BRII-179 and BRII-835, with BRII-179 (a recombinant protein-based immunotherapeutic) also in Phase 1b/2a, and BRII-835 having successfully completed Phase 2 for chronic HBV patients. The company also offers the Amubarvimab/romlusevimab combination as a treatment for COVID-19. Beyond these, Brii Biosciences is advancing BRII-296 for PPD and BRII-297 for various depressive conditions, alongside several agents targeting highly resistant infections: BRII-636, BRII-672, and BRII-693 are designed to combat multi-drug and extensively drug-resistant (MDR/XDR) gram-negative bacteria, while BRII-658 is under development for MDR/XDR tuberculosis and non-tuberculosis mycobacterial infections.
- ISIN
- KYG1645A1094
- Founded
- 2017
- Listed since
- Jul 13, 2021
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Greenland Mines LtdNasdaqCM: GRML | $80.35M | $5.54 | -7.97% |
| GlycoNex IncorporationTPEX: 4168 | $80.23M | NT$22.80 | +1.79% |
| BioPorto A/SCPSE: BIOPOR | $79.36M | Dkr1.04 | -2.80% |
| Nordicus Partners CorporationOTCPK: NORD | $79.33M | $4.08 | +1.77% |
| Pelthos Therapeutics Inc.NYSEAM: PTHS | $78.48M | $20.29 | -1.02% |
| Cell Biotech Co., Ltd.KOSDAQ: A049960 | $78.19M | ₩15,360.00 | -1.54% |
| CORESTEMCHEMON Inc.KOSDAQ: A166480 | $77.21M | ₩2,340.00 | +1.08% |
| Heron Therapeutics, Inc.NasdaqCM: HRTX | $77.10M | $0.39 | -3.82% |
Figures last refreshed Oct 11, 2026.